Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PLRX with free AI briefings, catalyst countdowns, and dilution alerts.

PLRX · PLIANT THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$175.2M Cash on Hand
32.8mo Cash Runway
Follow PLRX by email Get an email when PLRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PLRX, unsubscribe in one click. Privacy

📣 What PLRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bexotegrast (PLN-74809) Idiopathic Pulmonary Fibrosis Phase 2 · NCT06097260 Terminated
AlphaVbeta1/8 Inhibitor PLN-101095 Advanced or Metastatic Solid Tumor Phase 1 · NCT06270706 Recruiting
Fluorine F 18 FP-R01-MG-F2 Idiopathic Pulmonary Fibrosis Early Phase 1 · NCT03183570 Completed

Also used in these trials (approved or third-party drugs, not PLRX's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PLRX holds $175.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $16M/quarter from operations, an estimated runway of 32.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PLRX files for a raise →

👥 Who Owns PLRX

Insiders 3.1% Other 5%+ holders 9.5% Institutions (104 holders) 76.7% Public and other holders 10.7%
HolderTypeShares% of sharesAs of
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13D) 5,859,044 9.45% 2025-03-03
ADAR1 Capital Management, LLC Institution (13G, 5%+) 5,509,724 8.89% 2026-06-30
Bernard Coulie
President and CEO, Director · +3.18M options
Insider 914,918 1.48% 2026-01-20
Keith Lamont Cummings
Chief Financial Officer · +992,495 options
Insider 297,214 0.48% 2026-01-20
Hans Hull
Chief Business Officer · +80,300 options
Insider 265,693 0.43% 2025-01-23
Eric Lefebvre
Chief Medical Officer · +91,300 options
Insider 240,224 0.39% 2025-01-23
Mike Ouimette
General Counsel & Corp. Sec'y · +70,000 options
Insider 105,544 0.17% 2025-01-23
Lily Cheung
Chief Human Resource Officer · +526,750 options
Insider 44,847 0.07% 2026-01-20
Minnie Kuo
Chief Operating Officer · +545,200 options
Insider 37,806 0.06% 2026-01-20

Share count 61,990,635 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PLRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.